Hikma Pharmaceuticals (HIK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,836.00p
   
  • Change Today:
      15.00p
  • 52 Week High: 2,340.00
  • 52 Week Low: 1,740.00
  • Currency: UK Pounds
  • Shares Issued: 221.89m
  • Volume: 250,635
  • Market Cap: £4,073.84m
  • RiskGrade: 125

Deal with Barclays    Trade now with Barclays Stockbrokers

HIK Overview

Hikma is an international pharmaceutical company conducting operations through three businesses: generic pharmaceuticals, branded pharmaceuticals and injectable pharmaceuticals. The company sells 113 branded and non-branded generic pharmaceutical products in 34 countries worldwide. The majority of Hikma’s operations are in the United States, the Middle East and North Africa Region and Europe.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover 2.8 2.7
Op Mrgn 19.6% 21.6%
ROCE 24.3%  
Latest F'cast
P/E n/a 10.8
PEG n/a 5.1
Pr/Revenue n/a 1.2
Pr/Book n/a  
Latest F'cast
Revenue 8.8% -21.6%
PBT 61.9% 16.6%
EPS 0.4% 2.1%
DPS 11.1% -43.1%

HIK Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 2,341.00 558.00 172.90¢ 19.7 1.3 +15% 50.00¢ 1.5%
31-Dec-21 2,553.00 544.00 194.80¢ 15.4 1.2 +13% 54.00¢ 1.8%
31-Dec-22 2,517.00 233.00 181.00¢ 11.6 n/a -7% 56.00¢ 2.7%
31-Dec-23 2,875.00 281.00 223.00¢ 10.9 0.5 +23% 72.00¢ 3.0%
31-Dec-24 3,127.00 455.00 224.00¢ 12.0 n/a 0% 80.00¢ 3.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

HIK Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 3,316.69 717.55 168.73p 10.9 5.2 +2% 61.52p 0.0%
31-Dec-26 3,488.81 789.66 186.59p 9.8 0.9 +11% 66.03p 0.0%
31-Dec-27 3,712.94 865.45 207.47p 8.8 0.8 +11% 73.00p 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

HIK Company Announcements

Director/PDMR Shareholding 22-Aug-2025 12:02 RNS
Director/PDMR Shareholding 13-Aug-2025 13:51 RNS
Director/PDMR Shareholding 08-Aug-2025 12:59 RNS

HIK ShareCast News

Director dealings: Hikma Pharmaceuticals directo... 22-Aug-2025 ShareCast
Hikma on track to meet FY expectations despite H... 07-Aug-2025 ShareCast
Broker tips: Kingfisher, Accesso, Hikma 20-May-2025 ShareCast

HIK Top Newspaper Links

Hikma boosts injectables business with $300m deal 29-May-2014 Telegraph
MARKET REPORT: Shares jump as Hikma Pharmaceutic... 08-May-2014 Daily Mail
Hikma prepares return to Libya 26-Aug-2011 The Independent

Latest HIK Director Deals

Traded Action Notifier PriceAmountValue
22-Aug-25 Buy Laura Balan Balan 1,820.70p 3,500 £63,724.50
07-Aug-25 Buy Mazen Darwazah 1,756.00p 200,000 £3,511,999.89
30-May-25 Transfer From Mazen Darwazah 0.000p 36,171 £0.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

HIK Market Data

Currency UK Pounds
Share Price 1,836.00p
Change Today 15.00p
% Change 0.82 %
52 Week High 2,340.00
52 Week Low 1,740.00
Volume 250,635
Shares Issued 221.89m
Market Cap £4,073.84m
RiskGrade 125

HIK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
74.3% below the market average74.3% below the market average74.3% below the market average74.3% below the market average74.3% below the market average
31.71% above the sector average31.71% above the sector average31.71% above the sector average31.71% above the sector average31.71% above the sector average
Price Trend
51.95% below the market average51.95% below the market average51.95% below the market average51.95% below the market average51.95% below the market average
13.64% above the sector average13.64% above the sector average13.64% above the sector average13.64% above the sector average13.64% above the sector average
Income
38.55% above the market average38.55% above the market average38.55% above the market average38.55% above the market average38.55% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
42.16% above the market average42.16% above the market average42.16% above the market average42.16% above the market average42.16% above the market average
3.45% above the sector average3.45% above the sector average3.45% above the sector average3.45% above the sector average3.45% above the sector average

What The Brokers Say

Strong Buy 6
Buy 3
Neutral 3
Sell 0
Strong Sell 0
Total 12
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

HIK Dividends

  Latest Previous
  Interim Final
Ex-Div 14-Aug-25 20-Mar-25
Paid 18-Sep-25 01-May-25
Amount 36.00¢ 48.00¢

Trades for 22-Aug-2025

Time Volume / Share Price
16:26 1 @ 1,837.00p
16:25 17 @ 1,838.00p
16:25 197 @ 1,837.00p
16:19 6 @ 1,838.00p
16:19 6 @ 1,838.00p

HIK Key Personnel

CEO Riad Mishlawi

Top of Page